StreetInsider.com News Articles

Muna Therapeutics names former iTeos CEO to lead company

Tue, 30 Jun 2026 07:01:05 -0400

Muna Therapeutics announced a chief executive transition, with Michel Detheux, Ph.D., appointed CEO effective June 29, 2026, replacing founding CEO Rita Balice-Gordon, Ph.D., who will join the company's board of directors.

Detheux previously served as founder, president, and CEO of iTeos Therapeutics (NASDAQ: ITOS), where he raised more than $1.2 billion, grew the company to 180 employees across the U.S. and Europe, and secured a $2 billion collaboration with GSK.

Muna, headquartered in Copenhagen, Denmark, with U.S. operations, focuses on therapies for neurodegenerative diseases including Alzheimer's, Parkinson's, and ALS. Its lead asset, MNA-001, is a small-molecule TREM2 agonist currently completing Phase 1

Muna Therapeutics Announces CEO Transition as Clinical Pipeline Advances

Tue, 30 Jun 2026 07:00:00 -0400

After leading Muna's evolution into a clinical-stage company, Rita Balice-Gordon, Ph.D., will step down and join the Board of Directors; former iTeos President & CEO Michel Detheux, Ph.D., appointed Chief Executive Officer

Company remains focused on developing new therapies to treat neurodegenerative diseases like Alzheimer's, Parkinson's, and ALS, with lead TREM2 agonist on track to enter Phase 2 studies in early Alzheimer's in early 2027

COPENHAGEN, Denmark and BOSTON, June 30, 2026 /PRNewswire/ -- Muna Therapeutics (Muna), a biotechnology company pioneering novel therapeutics for neurodegenerative diseases, today announced a

Muna Therapeutics Announces CEO Transition as Clinical Pipeline Advances

Tue, 30 Jun 2026 07:00:00 -0400

COPENHAGEN, Denmark and BOSTON, June 30, 2026 /PRNewswire/ -- Muna Therapeutics (Muna), a biotechnology company pioneering novel therapeutics for neurodegenerative diseases, today announced a

Form 15-12G iTeos Therapeutics, Inc.

Mon, 08 Sep 2025 16:16:00 -0400

si-local-file:///var/storage/secattach/20250908/25309140.html

Form 15-12G iTeos Therapeutics, Inc.

Mon, 08 Sep 2025 16:16:00 -0400

si-local-file:///var/storage/secattach/20250908/25309140.html

Form EFFECT iTeos Therapeutics, Inc.

Fri, 05 Sep 2025 06:03:00 -0400

si-local-file:///var/storage/secattach/20250905/25300623.html

Form EFFECT iTeos Therapeutics, Inc.

Fri, 05 Sep 2025 06:03:00 -0400

si-local-file:///var/storage/secattach/20250905/25300623.html

Form SCHEDULE 13D/A iTeos Therapeutics, Inc. Filed by: TANG CAPITAL MANAGEMENT LLC

Wed, 03 Sep 2025 16:15:00 -0400

si-local-file:///var/storage/secattach/20250903/25292327.html

Form SCHEDULE 13D/A iTeos Therapeutics, Inc. Filed by: TANG CAPITAL MANAGEMENT LLC

Wed, 03 Sep 2025 16:15:00 -0400

si-local-file:///var/storage/secattach/20250903/25292327.html

Form 4 iTeos Therapeutics, Inc. For: Aug 29 Filed by: Lee David K

Fri, 29 Aug 2025 16:31:00 -0400

si-local-file:///var/storage/secattach/20250829/25277515.html

Form 4 iTeos Therapeutics, Inc. For: Aug 29 Filed by: Lee David K

Fri, 29 Aug 2025 16:31:00 -0400

si-local-file:///var/storage/secattach/20250829/25277515.html

Form 4 iTeos Therapeutics, Inc. For: Aug 29 Filed by: Detheux Michel

Fri, 29 Aug 2025 16:31:00 -0400

si-local-file:///var/storage/secattach/20250829/25277517.html

Form 4 iTeos Therapeutics, Inc. For: Aug 29 Filed by: Detheux Michel

Fri, 29 Aug 2025 16:31:00 -0400

si-local-file:///var/storage/secattach/20250829/25277517.html

Form 4 iTeos Therapeutics, Inc. For: Aug 29 Filed by: Call Matthew

Fri, 29 Aug 2025 16:31:00 -0400

si-local-file:///var/storage/secattach/20250829/25277529.html

Form 4 iTeos Therapeutics, Inc. For: Aug 29 Filed by: Call Matthew

Fri, 29 Aug 2025 16:31:00 -0400

si-local-file:///var/storage/secattach/20250829/25277529.html

Form 4 iTeos Therapeutics, Inc. For: Aug 29 Filed by: Hallal David